The La Jolla Institute for Allergy & Immunology (LIAI) is making significant strides in the battle against the avian "bird" flu, with pre-clinical trials under way on a potential treatment conceived by one of its scientists. The Institute, a not-for-profit organization whose cutting-edge research focuses on infectious diseases and other immune system disorders, is also developing information for a "universal" flu vaccine, as well as researching a needle-free vaccine that would treat various influenza strains, including the avian flu.
The Institute, which launched an Emerging Infectious Disease and Biodefense Research Center in 2004, is conducting three major research initiatives to attack the influenza virus -- all of which may be applicable to the avian flu strain, known as the H5N1 virus. "We understand the devastating potential of an avian flu outbreak as well as the problems caused each year by the more conventional flu strains," said Mitchell Kronenberg, LIAI President and Scientific Director, noting that 200,000 Americans are hospitalized and 36,000 die each year from the flu. "Our researchers are working diligently to understand the cellular mechanisms that hold the key to preventing or treating influenza," he said. "We are particularly excited that our research shows promise against the avian flu, as that may be the most urgent health issue now facing the world."
A potential treatment for the avian flu involving human flu-fighting antibodies was conceived by LIAI scientist Hilde Cheroutre, Ph.D., and initiated through a collaborative effort of LIAI and Gemini Science, a biopharmaceutical research and development company and wholly-owned U.S. subsidiary of Kirin Brewery Co., Ltd. of Japan. Gemini moved forward in 2000 with laboratory testing on the antibodies, which have produced preliminary data showing positive results against numerous flu strains, including the H5N1 avian flu.
Bonnie Ward | EurekAlert!
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering